OBJECTIVES Humoral and cellular immune reactivity are reported for two neuroendocrine autoantigens—glutamic acid decarboxylase (GAD) and the protein tyrosine phosphatase IA-2—in a patient with the autoimmune type of stiff-man syndrome and insulin dependent diabetes (IDDM).
METHODS Antibodies and T cell proliferation against GAD and IA-2 and cytokine release of antigen stimulated T cells (IFN-γ) were determined before and several times during immunosuppressive therapy with prednisolone.
RESULTS Raised GAD antibodies against full length GAD65 or chimeric constructs were detected before therapy and they remained at a high concentration despite a marked clinical improvement during cortisone treatment. Antibodies to IA-2 were undetectable, but weak T cell responses to both GAD and IA-2 were seen before therapy and once on reduction of high cortisone dosages when the patient showed signs of clinical deterioration. Cytokine profiles showed increased IFN-γ production after stimulation with GAD or IA-2 suggesting increased activation of TH1 cells.
CONCLUSION Immunosuppressive therapy —even with extremely high doses of 500 mg a day—does not lead to the reduction of antibody concentrations in the periphery nor to a switch in epitope recognition of such antibodies despite clinical improvement. The amount of T cell reactivity to various antigens, however, may be a useful marker to monitor the effectiveness of immunotherapy.
- stiff-man syndrome
- T cell reactivity
- prednisolone therapy
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Stiff-man syndrome is a rare disorder of the CNS, characterised by painful spasms and progressive symmetric rigidity of the axial and proximal muscles.1 Three different aetiological subtypes of stiff-man syndrome have been described: an autosomal dominant disorder with early onset in childhood called stiff-baby syndrome,2stiff-man syndrome associated with breast cancer and characterised by autoantibodies to the 128 kDa synaptic vesicle associated protein amphiphysin,3 4 and the most common autoimmune stiff-man syndrome (60%) often associated with additional autoimmune diseases such as insulin dependent diabetes mellitus.5 6 The association of stiff-man syndrome and insulin dependent diabetes mellitus is, from an immunological point of view, extremely interesting, because the two diseases share a major autoantigen, the enzyme glutamic acid decarboxylase (GAD). GAD is located in the β cells of the pancreas and in the GABA producing neurons of the peripheral nervous system and CNS.7 In stiff-man syndrome, high GAD antibody (GADA) titres are characteristic and, although controversial, these have been suggested to cause functional impairment of the GABA mediated physiological process, thereby explaining the neurological symptoms. In accordance with this, treatment of patients by plasmapheresis and/or immunosuppressive agents such as prednisolone result in an improvement of neurological symptoms.8 However, no studies so far exist on the course of humoral and cellular immune markers during immune intervention therapy.
GADA recognises several epitopes within the GAD65 molecule, including two relatively stiff-man syndrome specific epitopes contained within the carboxy and amino terminal regions.9 Antibodies to other pancreatic islet proteins including insulin and the protein tyrosine phosphatase-like molecule IA-2 are also found in patients with insulin dependent diabetes mellitus. IA-2 antibodies (IA-2A) can be detected in a minority of patients with stiff-man syndrome, most,10 but not all11 having insulin dependent diabetes mellitus. β Cell death and decline of insulin release in insulin dependent diabetes mellitus are not considered to be causally related to antibodies, including GADA, but are more likely to be T cell mediated. T Cell proliferative responses to GAD65 and other islet autoantigens can be found in patients with insulin dependent diabetes mellitus,12 but as yet there have been no reports of cellular immunity to GAD in stiff-man syndrome.
To determine whether neurological symptoms in stiff-man syndrome are directly related to autoimmunity we investigated both humoral (antibodies) and cellular immune responses (T cell proliferation and cytokine release) to GAD65 and IA-2, in a patient with stiff-man syndrome and insulin dependent diabetes mellitus before and during immunosuppressive therapy with prednisolone.
Objectives and methods
Stiff-man syndrome was diagnosed in 1994 in a 51 year old man. He fulfilled all criteria established by Lorish et al13 as (1) prodome of rigidity and stiffness in axial muscles, (2) progression of rigidity and stiffness to include proximal limb muscles, (3) deforming of the spine, in this case lordosis, (4) superimposed spasms precipitated by sudden movement and noise, (5) normal muscle strength and sensory examination, (6) normal intellect, (7) the classic EMG findings (continuous normal motor unit firing, despite the patient’s intention to relax), and (8) a favourable response to oral administration of diazepam. One year after the diagnosis of stiff-man syndrome the patient had an overtly diabetic glucose tolerance test and was diagnosed as having insulin dependent diabetes mellitus. Partial strumectomy had been performed in 1984, but today it is not possible to determine whether the hyperthyroidism was caused by Graves‘ disease or by an adenoma of the thyroid gland. A kidney biopsy performed because of recurrent microhaematuria disclosed the rare syndrome of “thin basal membranes (200 nm)”. This is the first description of a patient with stiff-man syndrome with this extremely rare nephropathy.
The patient had GAD antibodies and islet cell antibodies, but no other organ specific or non-organ specific antibodies. Cell count and protein content in the CSF were normal without oligoclonal bands. GAD antibodies were not measured in CSF samples. The HLA type of the patient is HLA-A1,23; B8,50; DR3,3; DQA1*0501,0501; DQB1*0201,0201.
The patient was first treated with diazepam (3×2.5–5 mg/day) for one year. Diazepam was then no longer effective and the treatment was changed to baclofen (3×20–25 mg/day), also a GABAergic agonist. Clinical improvement was seen, but lasted only four weeks. Immunosuppressive therapy was therefore initiated, starting with 500 mg intravenous prednisolone from day 1 to 10, followed by oral administration and decreasing doses of 80 to 5 mg. Currently, after 400 days of therapy the patient has good mobility and is without rigidity with 5 mg prednisolone and 3×5 mg diazepam daily (figure A and B). An oral glucose tolerance test (OGTT) performed before immunosuppression, was clearly abnormal (0 min 170 mg%, 120 min 215 mg%, HbA1c 7.2%) compared with the OGTT of one year before, which indicated impaired glucose tolerance, but no overt diabetes (0 min 119 mg%, 120 min 190 mg%, HbA1c 5.8%), and insulin therapy was started in parallel with the corticosteroid treatment.
Serum samples for detection of antibodies and venous blood for isolation of peripheral blood lymphocytes for T cell proliferation assay were isolated at day−180 before immunosuppressive therapy and at day 0, 5, 10, 20, 30, 50, 100, and 201 of the therapy. Blood samples were obtained in the morning before administration of steroid medication. Assays were performed blinded without knowledge of the clinical status of the patient.
AUTOANTIBODIES TO GAD, GAD EPITOPES, IA-2, IAA, AND ICA
Antibodies to GAD (GADA) and IA-2 (IA-2A) were analysed by radioligand binding assays as previously described.14Serum samples were tested for IAA using a competitive fluid phase radiobinding assay and expressed in nU/ml insulin precipitated.15 The threshold of positivity for GADA (13 U), IA-2A (5 U), and IAA (49 nU/ml) were defined as the 99th percentile of antibody concentrations in a control reference population. Undiluted serum samples were screened for conventional ICA-IgG by means of indirect immunofluorescence15 and titres expressed in Juvenile Diabetes Foundation units (JDF U, threshold 5 JDF U). To detect GAD antibodies reactive with epitopes contained within the amino terminal, middle, and carboxy terminal regions of GAD65, GAD65/GAD67 chimeric constructs and GAD65 deletion constructs similar to those previously described16 17 were prepared. Human GAD65 and GAD67 cDNAs in the pGEM3 vector18 were used as the source for the chimeric constructs. GAD651–94/GAD67101–593, GAD651–360/GAD67369–593, and GAD671–452/GAD65444–585 chimeric constructs and the deletion constructs GAD65233–585, GAD65290–585, and GAD65290–511 were used. All constructs were under the control of the SP6 promotor. Antibody binding to in vitro transcribed and translated 35S-labelled proteins was measured as previously described.19 Results were expressed as an antibody index relative to a serum from a patient with stiff-man syndrome with high titre GADAs.
T CELL STIMULATION TEST AND CYTOKINE DETERMINATION
Blood samples were analysed for Tcell reactivity to GAD and IA-2 as previously described.20 To exclude interassay variability during follow up, lymphocytes before and after therapy from all patient visits were frozen and, after completion of the study, tested in one T cell proliferation assay. Cells were frozen in 50% FKS and 10% dimethylsulphoxide (DMSO) and stored for 48 hours at −80°C and afterwards in liquid nitrogen. By using this standardised freezing protocol in previous experiments we did not find significant differences between fresh and frozen cells for T cell reactivity to GAD and IA-2 (data not shown). Results were expressed as SI (SI=cpm peripheral blood lymphocytes in the presence of antigen/cpm peripheral blood lymphocytes in medium alone). All antigens were tested in triplicate. Recombinant GAD65 was produced in a baculovirus system, purified by immobilised metal affinity chromatography on a chelate sepharose column (Elias, Freiburg, Germany), and tested in concentrations of 0.25, 0.5, 2.5, and 5 μg/ml. The intracellular domain of tyrosine phosphatase IA-2 was produced as a biotin labelled protein from clone IA-2ic (residues 603–98021), which was provided to us by M Christie (Department of Medicine, King’s College of Medicine and Dentistry, London, UK). After purification, the proteins were used at a concentration of 0.1, 1, 5, and 10 μg/ml. GAD65 and IA-2 did not contain significant concentrations of endotoxin (GAD65 <0.06 EU/ml, IA-2 <0.06, medium <0.06 EU/ml). Furthermore, in previous studies12 20 we did not detect significant differences between stimulation indices of GAD65 and IA-2 in normal controls suggesting that potential Escherichia coli contaminations of IA-2 had no major effect themselves on T cell stimulation compared with the baculovirus product GAD65. As a positive control, tetanus toxoid (Boehringer, Germany; 0.015 U/ml) and phytohaemagglutinin (PHA) (Difco, Detroit, Michigan; 0.05%) was used. The nuclear antigen La (Elias, Freiburg, Germany; 1 μg/ml) produced in a baculovirus system and purified the same way as GAD65 was included in each assay. Cytokine supernatants were generated by the T cell stimulation test described above and 100 μl supernatants were harvested after 72 hours and tested for IFN-γ with commercial enzyme linked immunosorbent assay (ELISA) kits (Laboserv, Giessen, Germany). The detection range was 4–1000 pg/ml for IFN-γ.
Immunosuppressive therapy was initiated after diazepam and baclofen mono-therapy had lost effect. The first dose of prednisolone (2×250 mg daily) injected intravenously led to a complete disappearance of previously described symptoms within 3–4 hours. After 10 days the therapy was changed to oral medication and the doses were successively decreased to 5 mg/day. On day 30 of therapy the patient relapsed with rigidity and stiffness. The prednisolone dose was increased to 10 mg with additional 3×5 mg of diazepam/day. On day 201 prednisolone was reduced to 5 mg/day together with 3×5 mg diazepam. His condition improved and on day 400 he had good mobility and much less muscle rigidity and stiffness than before the therapy.
At diagnosis the patient had raised concentrations of GADA. Raised antibody concentrations were found against the GAD651–94/GAD67101–593 (amino terminal epitope), GAD651–360/GAD67369–593, and GAD671–452/GAD65444–585 (carboxy terminal epitope) chimeric constructs, but not the deletion constructs. During the course of immunosuppressive therapy no change in GADA titres against full length GAD65 (figure A) or chimeric constructs were found and no relation between circulating GADA titres and clinical patterns was seen (figure A and B). The patient also had ICAs and IAAs. The ICAs fluctuated and were not detectable before immunosuppression and in one sample during the course of immunotherapy. The IAAs increased after insulin dependent diabetes mellitus diagnosis and exogenous insulin therapy. IA-2As were undetectable in all samples (figure A).
T CELL STIMULATION TEST AND CYTOKINE CONCENTRATIONS
Before immunosuppressive therapy T cells responded to GAD65 (SI=4) and IA-2 (SI=6.2) (figure B). High dose steroid medication resulted in decreased cellular reactivity to GAD and IA-2 together with clinical improvement of the patient. On day 30 (reduction of prednisolone therapy to 5 mg/day) rigidity and stiffness returned followed by increased T cell responses to GAD65 and IA-2 (SIGAD=3.4 and SIIA-2=6.2, respectively). A subsequent increase in steroid therapy (10 mg/day) which resulted in improved mobility was accompanied by a persistent decrease in cellular reactivity to GAD65 and IA-2. T cell reactivity to the control antigens, tetanus toxoid, and PHA was also influenced by immunosuppressive therapy (as shown for tetanus in figure B). On day 30 when steroid therapy was reduced and clinical symptoms returned, a sixfold increase of T cell reactivity to tetanus toxoid (figure B) and a threefold increase in proliferation to PHA (data not shown) were seen. The concentrations of IFN-γ as a marker of TH1 dominated T cell response, were measured in supernatants of T cell stimulation tests. At initiation of immunosuppressive therapy and on day 30 (remission of stiff-man syndrome symptoms) high concentrations of IFN-γ were detected in response to both antigens; T cells incubated with GAD65 secreted 183 and 175 pg/ml respectively and T cells incubated with IA-2 secreted considerably higher IFN-γ concentrations—namely, >1000 pg/ml. At all time points T cell responses directed against either GAD65 or IA-2 were accompanied with high IFN-γ concentrations. Cytokine concentrations to both antigens were dependent on antigen concentrations.
Discussion and conclusions
The aetiology and pathogenic mechanisms leading to stiff-man syndrome are still unknown. Antibodies to glutamic acid decarboxylase which are usually found in extremely high titres in such patients (10–1000-fold higher than titres found in insulin dependent diabetes mellitus without stiff-man syndrome) have been discussed as being causally responsible for the neurological disorder. In addition, non-specific inflammatory reactions and T cells have also been suggested as being involved.22 23 We report a patient with classic clinical symptoms of stiff-man syndrome and relatively high titres of GADAs.24 Despite clinical improvement, circulating GADA titres against full length GAD65 or GAD65/GAD67 chimeric constructs were stable during immunosuppression with corticosteroids. This indicates that immunotherapy had neither an effect on the concentration of circulating antibodies nor on the epitope binding characteristics of antibodies. Similar findings have been reported for several other autoimmune disorders in which antibody concentrations show no correlation with clinical symptoms.25
By contrast with the high concentrations of GADAs, T cell responses to GAD were low. In addition, raised T cell reactivity was found not only after stimulation with GAD, but also with the insulin dependent diabetes mellitus related autoantigen IA-2. Despite this, T cell proliferation itself was more closely related to neurological symptoms than antibody concentrations . T cell reactivity, including that against control antigens, correlated with the corticosteroid therapy and the clinical status of the patient, showing the highest reactivity before steroid treatment and during reduced doses of steroids at day 30 when the patient relapsed and showed clinical deterioration. This is in agreement with the reported finding that corticosteroids inhibit T cell proliferation and cytokine production in antigen stimulated T cells26 and with previous findings describing parallel changes of T cell reactivity and a clinical score in three of six patients with myasthenia gravis treated with immunesuppressive therapy (azathioprine).27 A modulation of synaptic transmission by corticosteroids is another possible mechanism by which the rapid clinical improvement may be explained. Such effects have not been reproducibly shown for corticosteroids, but agonistic as well as antagonistic effects of neurosteroids have been found at the GABAA-receptor,28 and therefore such a mechanism cannot be excluded.
In summary, we conclude and confirm that high doses of steroids—despite having no effect on antibody titres—induce remission in patients with stiff-man syndrome which can be sustained under low dose therapy for more than one year. A general increase of T cell reactivity to various antigens was found before immunotherapy and once on withdrawal of high cortisone dosages. Although increased T cell reactivity was not specific for GAD it showed an intriguing correlation with clinical symptoms. Sstudies on T cell proliferation may therefore become a useful marker to monitor immunosuppression.
We thank Professor E Albert (Laboratory of Immunogenetics, University Munich, Germany) for HLA typing and U Mollenhauer, S Seggewiβ, and J Vordemann for technical assistance. This study was supported by grants of the Deutsche Forschungsgemeinschaft DFG (Zi 310/5–4).